Filing Details

Accession Number:
0001140361-14-031042
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-06 16:11:59
Reporting Period:
2014-08-06
Filing Date:
2014-08-06
Accepted Time:
2014-08-06 16:11:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1581720 Loxo Oncology Inc. LOXO Pharmaceutical Preparations (2834) 462996673
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250195 Steve Elms 888 Seventh Avenue
30Th Floor
New York NY 10106
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-06 2,850,709 $0.00 3,039,416 No 4 C Indirect Held by Aisling Capital III, LP
Common Stock Acquisiton 2014-08-06 413,077 $13.00 3,452,493 No 4 P Indirect Held by Aisling Capital III, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect Held by Aisling Capital III, LP
No 4 P Indirect Held by Aisling Capital III, LP
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2014-08-06 2,343,749 $0.00 2,343,749 $0.00
Common Stock Series B Preferred Stock Disposition 2014-08-06 506,960 $0.00 506,960 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. All shares of Common Stock issued upon conversion were aggregated.
  2. The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP. Mr. Elms is a Managing Partner of Aisling GP. Aisling GP has established an investment committee that has voting and dispositive power over the shares held by Aisling, of which Mr. Elms is a member. Mr. Elms disclaims beneficial ownership of these securities held directly by Aisling and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or any other purposes, except to the extent of his pecuniary interest therein.